Humana Medicare Advantage has updated its prior authorization policy for Epclusa (sofosbuvir/velpatasvir), a hepatitis C medication. The policy requires prior authorization for chronic hepatitis C diagnosis and approves treatment for 12 weeks based on AASLD guidelines.
Get alerts when payers change rules like this one
We check Humana and other payers every day and email you when a change matches your specialty and state.
01Billing team must obtain prior authorization before prescribing Epclusa (sofosbuvir/velpatasvir) tablets or oral pellets for Medicare Advantage patients.
02Verify patient has chronic hepatitis C diagnosis documented.
03Submit requests through Humana's portal at www.humana.com/PAL.
04Claims without prior authorization will be denied.
Original notice
Epclusa® (sofosbuvir/velpatasvir) (Revised)
mcp.humana.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.